Obseva Logo highresolution.jpg
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses
May 25, 2022 01:00 ET | ObsEva SA
-Data featured in two oral presentations at the 8th Society of Endometriosis and Uterine Disorders Congress and a poster presentation at the International Society of Gynecological Endocrinology 20th...
Obseva Logo highresolution.jpg
ObsEva Announces Appointment of Annette Clancy as Chair of the Board of Directors
May 19, 2022 07:05 ET | ObsEva SA
GENEVA, Switzerland May 19, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced the appointment...
Obseva Logo highresolution.jpg
ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2022 Annual General Meeting held on May 18, 2022
May 19, 2022 07:00 ET | ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – May 19, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and...
Obseva Logo highresolution.jpg
ObsEva Announces Appointment of Annette Clancy as Chair of the Board of Directors
May 19, 2022 01:05 ET | ObsEva SA
GENEVA, Switzerland May 19, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced the appointment...
Obseva Logo highresolution.jpg
ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2022 Annual General Meeting held on May 18, 2022
May 19, 2022 01:00 ET | ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – May 19, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and...
Obseva Logo highresolution.jpg
ObsEva Announces First Quarter 2022 Financial Results and Provides Corporate Update
May 17, 2022 07:00 ET | ObsEva SA
-Linzagolix for uterine fibroids: Received confirmation of positive CHMP opinion for marketing authorization application; United States NDA PDUFA date in Q3:22- -Linzagolix for endometriosis:...
Obseva Logo highresolution.jpg
ObsEva Announces First Quarter 2022 Financial Results and Provides Corporate Update
May 17, 2022 01:00 ET | ObsEva SA
-Linzagolix for uterine fibroids: Received confirmation of positive CHMP opinion for marketing authorization application; United States NDA PDUFA date in Q3:22- -Linzagolix for endometriosis:...
Obseva Logo highresolution.jpg
ObsEva to Present at the H.C. Wainwright Global Investment 2022 Conference
May 16, 2022 07:00 ET | ObsEva SA
GENEVA, Switzerland May 16, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that Company...
Obseva Logo highresolution.jpg
ObsEva to Present at the H.C. Wainwright Global Investment 2022 Conference
May 16, 2022 01:00 ET | ObsEva SA
GENEVA, Switzerland May 16, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that Company...
Obseva Logo highresolution.jpg
ObsEva to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business Update
May 12, 2022 07:00 ET | ObsEva SA
GENEVA, Switzerland – May 12, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that it plans...